Search results
Showing 6316 to 6330 of 8973 results
Recommendation ID NG25/1 Question Prophylactic cervical cerclage compared with prophylactic vaginal progesterone for preventing preterm
Recommendation ID NG25/4 Question Magnesium sulfate for neuroprotection: bolus plus infusion compared with bolus alone:- What is the clinical
Recommendation ID NG25/3 Question Effectiveness of 'rescue' cerclage:- What is the clinical effectiveness of 'rescue' cerclage in improving
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe
Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief
Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) will help bring medicines to patients faster.
Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care
Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
Sophie Cooper, senior scientific adviser at NICE, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.